As Microsoft (MSFT) Stock Price Declined, Holder Perkins Coie Trust Company Lowered Position; Progenics Pharmaceuticals In (PGNX) Share Value Declined While Ardsley Advisory Partners Trimmed by $510,000 Its Stake

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Logo

Ardsley Advisory Partners decreased its stake in Progenics Pharmaceuticals In (PGNX) by 3.99% based on its latest 2018Q3 regulatory filing with the SEC. Ardsley Advisory Partners sold 85,000 shares as the company’s stock declined 41.43% with the market. The hedge fund held 2.05M shares of the major pharmaceuticals company at the end of 2018Q3, valued at $12.82M, down from 2.13M at the end of the previous reported quarter. Ardsley Advisory Partners who had been investing in Progenics Pharmaceuticals In for a number of months, seems to be less bullish one the $405.80 million market cap company. The stock increased 3.90% or $0.18 during the last trading session, reaching $4.8. About 562,764 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has declined 27.42% since January 10, 2018 and is downtrending. It has underperformed by 27.42% the S&P500. Some Historical PGNX News: 25/04/2018 – Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; 02/04/2018 – Progenics Presenting at Conference Apr 9; 02/05/2018 – Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection; 11/05/2018 – PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT; 22/05/2018 – Progenics Pharma: Data Support Prognostic Utility of aBSI as Imaging Biomarker for Survival With Castration-Resistant Prostate Cancer; 22/03/2018 – PROGENICS SAYS FDA EXTENDS NDA REVIEW FOR AZEDRA TO JULY 30; 19/03/2018 – PROGENICS STUDY OF AZEDRA ACHIEVED PRIMARY, SECONDARY ENDPOINTS; 19/03/2018 – CORRECT: PGNX’S AZEDRA CORRELATION B/W RESPONSE AND ENDPOINTS; 22/04/2018 – DJ Progenics Pharmaceuticals Inc, Inst Holders, 1Q 2018 (PGNX); 31/05/2018 – Progenics’ Artificial Intelligence Technology for Automated Analysis of PSMA Targeted Prostate Cancer Images to be Featured at the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Perkins Coie Trust Company decreased its stake in Microsoft Corp (MSFT) by 4.26% based on its latest 2018Q3 regulatory filing with the SEC. Perkins Coie Trust Company sold 3,627 shares as the company’s stock declined 1.64% with the market. The institutional investor held 81,436 shares of the prepackaged software company at the end of 2018Q3, valued at $9.31M, down from 85,063 at the end of the previous reported quarter. Perkins Coie Trust Company who had been investing in Microsoft Corp for a number of months, seems to be less bullish one the $793.47 billion market cap company. The stock decreased 0.88% or $0.92 during the last trading session, reaching $103.35. About 20.25M shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 30.43% since January 10, 2018 and is uptrending. It has outperformed by 30.43% the S&P500. Some Historical MSFT News: 25/04/2018 – Marc Jacobs fuels creativity and innovative design with the Microsoft Cloud; 12/04/2018 – BlackRock snags more assets in market rout, boosts profit; 29/03/2018 – MICROSOFT – TERRY MYERSON WILL LEAVE CO; 23/03/2018 – Time: Apple Is About to Release a Cheaper iPad to Take on Microsoft and Google; 26/04/2018 – Microsoft 3Q EPS 95c; 17/04/2018 – Gigamon Announces General Availability of GigaSECURE Cloud for Microsoft Azure; 26/04/2018 – MICROSOFT CFO HOOD COMMENTS ON CAPEX SPENDING IN INTERVIEW; 29/03/2018 – Parts of Microsoft’s Windows and Devices Group are getting pulled out and placed in other groups as its leader departs; 16/03/2018 – FTI Consulting’s Carlyn Taylor Named a Fellow of the American College of Bankruptcy; 17/04/2018 – Ionic Security and Microsoft collaborate to simplify risk management and accelerate enterprise cloud adoption through Microsoft

More notable recent Microsoft Corporation (NASDAQ:MSFT) news were published by: Nasdaq.com which released: “Notable ETF Inflow Detected – IWV, MSFT, AAPL, V – Nasdaq” on December 14, 2018, also Nasdaq.com with their article: “Weekly Market Preview: Five Stocks To Watch For the Coming Week (MSFT, AMD, AMZN, GOOG, INTC) – Nasdaq” published on October 21, 2018, Nasdaq.com published: “Microsoft Stock: 3 Numbers Actually Worth Paying Attention To – Nasdaq” on August 21, 2018. More interesting news about Microsoft Corporation (NASDAQ:MSFT) were released by: Seekingalpha.com and their article: “Microsoft: Vulnerable At The Highs? – Seeking Alpha” published on October 22, 2018 as well as Nasdaq.com‘s news article titled: “After Hours Most Active for Dec 19, 2018 : F, TEVA, EEP, QQQ, EMB, AMD, MSFT, BAC, FOXA, CMCSA, DWDP, WFC – Nasdaq” with publication date: December 19, 2018.

Among 38 analysts covering Microsoft Corporation (NASDAQ:MSFT), 34 have Buy rating, 1 Sell and 3 Hold. Therefore 89% are positive. Microsoft Corporation had 216 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was maintained by UBS on Friday, October 23 with “Buy”. The firm has “Buy” rating by Piper Jaffray given on Friday, July 21. Cowen & Co maintained it with “Market Perform” rating and $59 target in Friday, April 1 report. Wunderlich maintained Microsoft Corporation (NASDAQ:MSFT) on Friday, January 29 with “Hold” rating. The rating was maintained by Barclays Capital with “Buy” on Friday, January 12. The stock of Microsoft Corporation (NASDAQ:MSFT) has “Neutral” rating given on Tuesday, April 26 by Macquarie Research. The rating was upgraded by Cowen & Co to “Outperform” on Tuesday, May 24. The firm earned “Buy” rating on Monday, October 2 by Piper Jaffray. The firm earned “Hold” rating on Wednesday, July 20 by Wunderlich. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, January 27.

Since August 31, 2018, it had 0 buys, and 10 selling transactions for $54.07 million activity. BROD FRANK H sold 2,000 shares worth $214,363. Hood Amy sold $13.09 million worth of stock. Nadella Satya had sold 203,418 shares worth $21.70M. Hogan Kathleen T sold $4.45 million worth of stock or 40,000 shares.

Analysts await Microsoft Corporation (NASDAQ:MSFT) to report earnings on January, 30. They expect $1.09 EPS, up 13.54% or $0.13 from last year’s $0.96 per share. MSFT’s profit will be $8.37 billion for 23.70 P/E if the $1.09 EPS becomes a reality. After $1.14 actual EPS reported by Microsoft Corporation for the previous quarter, Wall Street now forecasts -4.39% negative EPS growth.

Investors sentiment decreased to 0.81 in Q3 2018. Its down 0.03, from 0.84 in 2018Q2. It turned negative, as 33 investors sold MSFT shares while 981 reduced holdings. 145 funds opened positions while 681 raised stakes. 5.28 billion shares or 0.60% less from 5.31 billion shares in 2018Q2 were reported. Troy Asset Mngmt Limited accumulated 2.76 million shares. Kingdon Capital Management Limited Liability Co, New York-based fund reported 268,000 shares. Anderson Hoagland reported 56,590 shares or 3.67% of all its holdings. Trustmark National Bank & Trust Department reported 0.73% in Microsoft Corporation (NASDAQ:MSFT). Clifford Swan Counsel Limited Liability Company has invested 2.51% in Microsoft Corporation (NASDAQ:MSFT). Mcrae Cap Mgmt invested in 124,753 shares. Causeway Mgmt Ltd Liability Co owns 2.07M shares for 2.38% of their portfolio. Hilton Mngmt Limited owns 0.19% invested in Microsoft Corporation (NASDAQ:MSFT) for 11,170 shares. Barometer Cap Mngmt Inc invested 2.52% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Channing Mgmt Llc holds 81,447 shares. Page Arthur B reported 3.88% in Microsoft Corporation (NASDAQ:MSFT). New Mexico Educational Retirement Board reported 2.98% stake. Oregon Public Employees Retirement Fund stated it has 1.75 million shares or 2.76% of all its holdings. Wedgewood Pa reported 3.5% in Microsoft Corporation (NASDAQ:MSFT). Jane Street Grp Inc Limited Liability reported 0.08% of its portfolio in Microsoft Corporation (NASDAQ:MSFT).

Among 6 analysts covering Progenics Pharm (NASDAQ:PGNX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 12 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, September 26 by Jefferies. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Brean Capital on Thursday, August 6. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Zacks on Friday, August 7. The stock has “Buy” rating by Needham on Friday, August 7. As per Friday, October 23, the company rating was upgraded by Jefferies. The rating was upgraded by Needham to “Strong Buy” on Monday, February 6. The stock has “Buy” rating by Needham on Tuesday, June 20. The stock has “Buy” rating by Aegis Capital on Thursday, October 27. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, August 9. As per Thursday, June 8, the company rating was maintained by Jefferies.

More notable recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Seekingalpha.com which released: “Progenics: Q2 Earnings And Outlook – Seeking Alpha” on August 03, 2018, also Seekingalpha.com with their article: “Progenics: What Is The Value Of The Imaging Pipeline? – Seeking Alpha” published on June 05, 2018, Seekingalpha.com published: “Progenics Pharmaceuticals prices equity offering, shares down 7% premarket – Seeking Alpha” on August 08, 2018. More interesting news about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were released by: Schaeffersresearch.com and their article: “2 Healthcare Stocks Sending Up Buy Signals – Schaeffers Research” published on August 21, 2018 as well as Seekingalpha.com‘s news article titled: “Progenics shares halted pending news – Seeking Alpha” with publication date: October 05, 2018.

Ardsley Advisory Partners, which manages about $862.45M and $742.11 million US Long portfolio, upped its stake in Polarityte Inc by 86,500 shares to 481,500 shares, valued at $9.20M in 2018Q3, according to the filing. It also increased its holding in Sunopta Inc (NASDAQ:STKL) by 1.44 million shares in the quarter, for a total of 4.41M shares, and has risen its stake in Xilinx Inc (NASDAQ:XLNX).

Investors sentiment decreased to 1.41 in 2018 Q3. Its down 0.44, from 1.85 in 2018Q2. It is negative, as 23 investors sold PGNX shares while 28 reduced holdings. 20 funds opened positions while 52 raised stakes. 73.30 million shares or 17.29% more from 62.50 million shares in 2018Q2 were reported. The Missouri-based Stifel Corp has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Great West Life Assurance Co Can owns 98,958 shares for 0% of their portfolio. Federated Invsts Pa owns 6.42M shares. Fosun Ltd has 398,588 shares. Ameriprise Financial Inc holds 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) or 475,354 shares. The California-based Reilly Advisors Ltd Limited Liability Company has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Armistice Cap Ltd Liability invested 2.32% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). British Columbia – Canada-based Numerixs Investment Technology Inc has invested 0.01% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). South Dakota Inv Council has 9,200 shares for 0% of their portfolio. Texas Permanent School Fund owns 52,759 shares. 388 were reported by Daiwa Secs Grp. Credit Suisse Ag invested in 78,520 shares or 0% of the stock. Northern Tru accumulated 0% or 1.08M shares. California Public Employees Retirement System has 144,415 shares for 0% of their portfolio. First Hawaiian Bancorp holds 300 shares.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 14. They expect $-0.07 EPS, up 66.67% or $0.14 from last year’s $-0.21 per share. After $-0.09 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.22% EPS growth.

Microsoft Corporation (NASDAQ:MSFT) Institutional Positions Chart